Nymox Pharmaceutical Corporation reported that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020. Certain tasks have been hampered by the Covid pandemic restrictions, similar to other companies in the sector. These remaining tasks are expected to be completed reasonably soon as the company regains the ability to retrieve required documentation from external sites and to complete other required tasks and on-site activities that were hindered due to the global restrictions in place.